Efficacy and safety of formoterol turbuhaler® when added to inhaled corticosteroid treatment in children with asthma
Authors:
- 12 January 2004
- journal article
- clinical trial
- Published by Wiley in Pediatric Pulmonology
- Vol. 37 (2) , 122-127
Abstract
This double‐blind, placebo‐controlled, randomized, parallel‐group, multicenter study was conducted in 302 children aged 6–11 years with asthma not optimally treated with inhaled corticosteroids alone. Patients continued with their existing dose of inhaled corticosteroids and in addition received placebo, formoterol 4.5 μg or formoterol 9 μg b.i.d., for 12 weeks (all delivered via Turbuhaler®). Terbutaline was available as reliever medication. The primary efficacy variable was change from baseline in morning peak expiratory flow (PEF); secondary efficacy variables included forced expiratory volume in 1 sec (FEV1), serial PEF measured over 12 hr, evening PEF, asthma symptom score, and quality of life. Compared with placebo, formoterol 4.5 μg and 9 μg improved morning PEF by 8 l/min (P = 0.035) and 11 l/min (P = 0.0045), respectively. Evening PEF and FEV1 were also significantly increased compared with placebo, with no statistically significant difference between formoterol doses. Lung‐function improvements compared with placebo were greater in the middle of the day. Twelve‐hour average serial PEF after 3 months increased by 24 l/min (95% CI, 9, 39 l/min) in the formoterol 9‐μg group, and by 14 l/min (95% CI, 0, 29 l/min) in the formoterol 4.5‐μg group. The incidence of severe exacerbations in both formoterol groups was numerically lower than in the placebo group, indicating that formoterol may have the potential to improve exacerbation control in children. Both formoterol doses were well‐tolerated, and tolerance to the drug's bronchodilator effect was not observed. Formoterol provided sustained improvements in lung function and was well‐tolerated in children with asthma suboptimally treated with inhaled corticosteroids alone. Pediatr Pulmonol. 2004; 37:122–127.Keywords
This publication has 15 references indexed in Scilit:
- Low Dose Inhaled Budesonide and Formoterol in Mild Persistent AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Bronchodilation and Bronchoprotection in Asthmatic Preschool Children from Formoterol Administered by Mechanically Actuated Dry-powder Inhaler and SpacerAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Choices of therapy for exercise-induced asthma in childrenAllergy, 2001
- Formoterol via Turbuhaler®gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescentsRespiratory Medicine, 2000
- Onset and duration of action of single doses of formoterol inhaled via turbuhaler®Respiratory Medicine, 1998
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potencyEuropean Respiratory Journal, 1997
- A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patientsEuropean Respiratory Journal, 1996
- Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double‐blind cross‐over study versus salbutamolClinical & Experimental Allergy, 1990
- Statement on Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease (COPD) and AsthmaAmerican Review of Respiratory Disease, 1987